Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,726.20 +203.62 (+0.29%) CMC Crypto 200
1,514.28 +25.73 (+1.73%)
PTCT May 2024 36.000 call
| Previous close | 1.1000 |
| Open | 1.1000 |
| Bid | 0.0000 |
| Ask | 2.9000 |
| Strike | 36.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.1000 - 1.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
ZacksPTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
PR NewswirePTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation. As a result, Translarna remains on the market and available for patients in Europe consistent with its current marketing authorization. The EC has asked the CHMP to further consider the to
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
